Identification of human T cell targets recognized during Chlamydia trachomatis genital infection

Journal of Infectious Diseases

Volumn 196, Issue 10, 2007, Pages 1546-1552

  Olsen, Anja Weinreich ^a   Follmann, Frank ^a   Højrup, Peter ^c   Leah, Robert ^a,d   Sand, Carsten ^b   Andersen, Peter ^a   Theisen, Michael ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Unizyme Laboratories A/S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CT583 ANTIGEN; CT603 ANTIGEN; CT610 ANTIGEN; GAMMA INTERFERON; UNCLASSIFIED DRUG; BACTERIAL DNA; PRIMER DNA;

AMINO ACID SEQUENCE; ARTICLE; CELL HETEROGENEITY; CELL LYSATE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEROTYPE; T LYMPHOCYTE; TARGET CELL; BLOOD; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

CASE-CONTROL STUDIES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DNA PRIMERS; DNA, BACTERIAL; HUMANS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 38449095531     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522524     Document Type: Article

References (47)

1. World Health Organization (WHO). Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: WHO, 2001. Available at: http://www.who.int/docstore/hiv/GRSTI. Accessed 27 September 2007.
2. Pearlman MD, McNeeley SG. A review of the microbiology, immunology, and clinical implications of Chlamydia trachomatis infections. Obstet Gynecol Surv 1992; 47:448-61.
3. Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med 2003; 349:2424-30.
4. Brunham RC. Human immunity to Chlamydia. In: Stephens RS, ed. Chlamydia intracellular biology, pathogenesis, and immunity. Washington, DC: ASM Press, 1999:211-238.
5. Jonsdottir K, Kristjansson M, Hjaltalin Olafsson J, Steingrimsson O. The molecular epidemiology of genital Chlamydia trachomatis in the greater Reykjavik area, Iceland. Sex Transm Dis 2003; 30:249-56.
6. Jurstrand M, Falk L, Fredlund H, et al. Characterization of Chlamydia trachomatis omp1 genotypes among sexually transmitted disease patients in Sweden. J Clin Microbiol 2001; 39:3915-9.
7. Dean D, Oudens E, Bolan G, Padian N, Schachter J. Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infections and histopathology in San Francisco. J Infect Dis 1995; 172:1013-22.
8. Millman K, Black CM, Johnson RE, et al. Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States. J Bacteriol 2004; 186:2457-65.
9. Brunham RC, Plummer FA, Stephens RS. Bacterial antigenic variation, host immune response, and pathogen-host coevolution. Infect Immun 1993; 61:2273-6.
10. Conway DJ. Natural selection on polymorphic malaria antigens and the search for a vaccine. Parasitol Today 1997; 13:26-9.
11. Igietseme JU, Ramsey KH, Magee DM, Williams DM, Kincy TJ, Rank RG. Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone. Reg Immunol 1993; 5:317-24.
12. Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995; 63:4661-8.
13. Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol 1997; 158:3344-52.
14. Reddy BS, Rastogi S, Das B, Salhan S, Verma S, Mittal A. Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women - implication for T-cell responses. Clin Exp Immunol 2004; 137:552-8.
15. Kelly KA. Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms. Int Rev Immunol 2003; 22:3-41.
16. Brunham RC, Kimani J, Bwayo J, et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis 1996; 173:950-6.
17. Cohen CR, Koochesfahani KM, Meier AS, et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon-γ. J Infect Dis 2005; 192:591-9.
18. Ortiz L, Demick KP, Petersen JW, et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J Immunol 1996; 157:4554-67.
19. + CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections. J Immunol 1999; 162:6855-66.
20. Gaston JS, Deane KH, Jecock RM, Pearce JH. Identification of 2 Chlamydia trachomatis antigens recognized by synovial fluid T cells from patients with Chlamydia induced reactive arthritis. J Rheumatol 1996; 23:130-6.
21. Deane KH, Jecock RM, Pearce JH, Gaston JS. Identification and characterization of a DR4-restricted T cell epitope within chlamydia heat shock protein 60. Clin Exp Immunol 1997; 109:439-45.
22. + T cells from humans infected with Chlamydia trachomatis. Clin Exp Immunol 2001; 126:488-93.
23. + T cells recognize the 60-kDa cysteine-rich outer membrane protein from Chlamydia trachomatis. J Immunol 2004; 173:6905-13.
24. Olsen AW, Follmann F, Jensen K, et al. Identification of CT521 as a frequent target of Th1 cells in patients with urogenital Chlamydia trachomatis infection. J Infect Dis 2006; 194:1258-66.
25. Arno JN, Xie C, Jones RB, Van Der Pol B. Identification of T cells that respond to serovar-specific regions of the Chlamydia trachomatis major outer membrane protein in persons with serovar E infection. J Infect Dis 1998; 178:1713-8.
26. Ortiz L, Angevine M, Kim SK, Watkins D, DeMars R. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans. Infect Immun 2000; 68:1719-23.
27. Brunelle BW, Sensabaugh GF. The ompA gene in Chlamydia trachomatis differs in phylogeny and rate of evolution from other regions of the genome. Infect Immun 2006; 74:578-85.
28. Stothard DR, Boguslawski G, Jones RB. Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein and examination of potential pathogenic determinants. Infect Immun 1998 66:3618-25.
29. Gobom J, Nordhoff E, Mirgorodskaya E, Ekman R, Roepstorff P. Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 1999; 34:105-16.
30. Stephens RS, Kalman S, Lammel C, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 1998; 282:754-9.
31. Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol 1995; 2:30-4.
32. Franken KL, Hiemstra HS, van Meijgaarden KE, et al. Purification of His-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif 2000; 18:95-9.
33. Higgins DG, Sharp PM. Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl Biosci 1989; 5:151-3.
34. McDonald JH, Kreitman M. Adaptive protein evolution at the Adh locus in Drosophila. Nature 1991; 351:652-4.
35. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 2003; 19:2496-7.
36. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989; 123:585-95.
37. Wakeley J. Polymorphism and divergence for island-model species. Genetics 2003; 163:411-20.
38. Kuon W, Holzhutter HG, Appel H, et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J Immunol 2001; 167:4738-46.
39. Polley SD, Tetteh KK, Lloyd JM, et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 2007; 195:279-87.
40. Conway DJ, Cavanagh DR, Tanabe K, et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 2000; 6:689-92.
41. Dean D, Millman K. Molecular and mutation trends analyses of omp1 alleles for serovar E of Chlamydia trachomatis: implications for the immunopathogenesis of disease. J Clin Invest 1997; 99:475-83.
42. Skipp P, Robinson J, O'Connor CD, Clarke IN. Shotgun proteomic analysis of Chlamydia trachomatis. Proteomics 2005; 5:1558-73.
43. Shaw AC, Gevaert K, Demol H, et al. Comparative proteome analysis of Chlamydia trachomatis serovar A, D and L2. Proteomics 2002; 2:164-86.
44. Belland RJ, Zhong G, Crane DD, et al. Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 2003; 100:8478-83.
45. Stenner-Liewen F, Liewen H, Zapata JM, Pawlowski K, Godzik A, Reed JC. CADD, a Chlamydia protein that interacts with death receptors. J Biol Chem 2002; 277:9633-6.
46. Netto LES, Chae HZ, Kang SW, Rhee SG, Stadtman ER. Removal of hydrogen peroxide by thiol-specific antioxidant enzyme (TSA) is involved with its antioxidant properties: TSA possesses thiol peroxidase activity. J Biol Chem 1996; 271:15315-21.
47. Belland RJ, Nelson DE, Virok D, et al. Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation. Proc Natl Acad Sci U S A 2003; 100:15971-6.